Canadian Journal of Gastroenterology and Hepatology

Review Article

Laparoscopic versus Open Surgery for Hepatocellular Carcinoma: A Meta-Analysis of High-Quality Case-Matched Studies

Table 4

Summary of recurrence and long-term survival.


Author	Group	Follow-up	R	Survival (time: month; rate: %)

Tranchart et al.	LH	29.7	10	1, 3, 5 y-DFS: 81.6, 60.9, 45.6; 1, 3, 5 y-OS: 93.1, 74.4, 59.5.
Tranchart et al.	OH	24.6	12	1, 3, 5 y-DFS: 70.2, 54.3, 37.2; 1, 3, 5 y-OS: 81.8, 73, 47.4.
Kim et al.	LH	21.8	7	MDFS: 13.4; 1 y-DFS: 84.6.
Kim et al.	OH	24.8	10	MDFS: 14.6; 1 y-DFS: 82.8.
Truant et al.	LH	35.7	16	5 y-DFS: 35.5; 5 y-OS: 70.
Truant et al.	OH	35.7	23	5 y-DFS: 33.6; 5 y-OS: 46.
Lee et al.	LH	35.4	15	1, 3, 5 y-DFS: 78.8, 51, 45.3; 1, 3, 5 y-OS: 86.9, 81.8, 76.0.
Lee et al.	OH	28.5	19	1, 3, 5 y-DFS: 69.2, 55.9, 55.9; 1, 3, 5 y-OS: 98, 80.6, 76.1.
Ahn et al.	LH	38.6	12	5 y-DFS: 67.8; 5 y-OS: 80.1.
Ahn et al.	OH	52.3	21	5 y-DFS: 54.8; 5 y-OS: 85.7.
Kim et al.	LH	47.9	11	MDFS: 15.4; MOS: 47.9; 1, 3, 5 y-DFS: 81.1, 61.7, 54.0; 1, 3, 5 y-OS: 100, 100, 92.2.
Kim et al.	OH	59.5	16	MDFS: 32.6; MOS: 59.5; 1, 3, 5 y-DFS: 78.6, 60.9, 40.1; 1, 3, 5 y-OS: 96.5, 92.2, 87.7.
Memeo et al.	LH	NR	25	1, 5, 10 y-DFS: 80, 19, 0; 1, 5, 10 y-OS: 88, 59, 12.
Memeo et al.	OH	NR	28	1, 5, 10 y-DFS: 60, 23, 9; 1, 5, 10 y-OS: 63, 44, 22.
Lee et al.	LH	22.7	NR	1, 3, 5 y-DFS: 60.5, 53.5, 53.5; 1, 3, 5 y-OS: 95.3, 89.7, 89.7.
Lee et al.	OH	44.4	NR	1, 3, 5 y-DFS: 81.5, 66.7, 58.6; 1, 3, 5 y-OS: 93.9, 89.5, 87.3.
Luo et al.	LH	35	20	MDFS: 21.
Luo et al.	OH	37	24	MDFS: 18.
Takahara et al.	LH	46.7	NR	1, 3, 5 y-DFS: 83.7, 58.3, 40.7; 1, 3, 5 y-OS: 95.8, 86.2, 76.8.
Takahara et al.	OH	51.7	NR	1, 3, 5 y-DFS: 79.6, 50.4, 39.3; 1, 3, 5 y-OS: 95.8, 84.0, 70.9.
Han et al.	LH	44.0	43	1, 3, 5 y-DFS: 69.7, 52.0, 44.2; 1, 3, 5 y-OS: 91.6, 87.5, 76.4.
Han et al.	OH	48.7	46	1, 3, 5 y-DFS: 74.7, 49.5, 41.2; 1, 3, 5 y-OS: 93.1, 87.8, 73.2.
Yoon et al.	LH	NR	16	1, 2, 3, 4 y-DFS: 82.0, 63.0, 56.0, 56.0; 1, 2, 3, 4 y-OS: 95.0, 92.0, 86.0, 86.0.
Yoon et al.	OH	NR	31	1, 2, 3, 4 y-DFS: 88.0, 79.0, 62.0, 62.0; 1, 2, 3, 4 y-OS: 98.0, 93.0, 84.0, 68.0.
Cheung et al.	LH	34.6	36	MDFS: 66.4; MOS: 136; 1, 3, 5 y-DFS: 87.7, 65.8, 52.2; 1, 3, 5 y-OS: 98.9, 89.8, 83.7.
Cheung et al.	OH	46.6	160	MDFS: 52.4; MOS: 120; 1, 3, 5 y-DFS: 75.2, 56.3, 47.9; 1, 3, 5 y-OS: 94, 79.3, and 67.4.
Sposito et al.	LH	39.3	NR	MDFS: 25.5; MOS: 48.8; 3, 5 y-DFS: 41, 25; 3, 5 y-OS: 75, 38.
Sposito et al.	OH	44.5	NR	MDFS: 31.7; MOS: 57.8; 3, 5 y-DFS: 44, 11; 3, 5 y-OS: 79, 46.
Jiang et al.	LH	NR	26	MDFS: 17; 5 y-DFS: 44.
Jiang et al.	OH	NR	30	MDFS: 15; 5 y-DFS: 40.
Komatsu et al.	LH	24.7	NR	3 y-DFS: 50.3; 3 y-OS: 73.4.
Komatsu et al.	OH	24.7	NR	3 y-DFS: 29.7; 3 y-OS: 69.2.
Yoon et al.	LH	NR	NR	2 y-DFS: 85.1; 2 y-OS: 100.
Yoon et al.	OH	NR	NR	2 y-DFS: 83.9; 2 y-OS: 88.8.
Xu et al.	LH	13.8	NR	1, 2 y-DFS: 95.5, 72.9; 1, 2 y-OS: 100, 85.7.
Xu et al.	OH	13.8	NR	1, 2 y-DFS: 93.5, 81.5; 1, 2 y-OS: 96.3, 86.7.

Follow-up was shown as median month; R: recurrence; DFS: disease-free survival rate; OS: overall survival rate; MDFS: median disease-free survival time; MOS: median overall survival time; y: year; NR: not reported.